Gilead Sciences Shares Outstanding 2010-2022 | GILD
Gilead Sciences shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
- Gilead Sciences shares outstanding for the quarter ending September 30, 2022 were 1.261B, a 0.08% decline year-over-year.
- Gilead Sciences 2021 shares outstanding were 1.262B, a 0.08% decline from 2020.
- Gilead Sciences 2020 shares outstanding were 1.263B, a 1.1% decline from 2019.
- Gilead Sciences 2019 shares outstanding were 1.277B, a 2.37% decline from 2018.
Gilead Sciences Annual Shares Outstanding
(Millions of Shares) |
| 2021 |
1,262 |
| 2020 |
1,263 |
| 2019 |
1,277 |
| 2018 |
1,308 |
| 2017 |
1,319 |
| 2016 |
1,358 |
| 2015 |
1,521 |
| 2014 |
1,647 |
| 2013 |
1,695 |
| 2012 |
1,583 |
| 2011 |
1,580 |
| 2010 |
1,747 |
| 2009 |
1,868 |
Gilead Sciences Quarterly Shares Outstanding
(Millions of Shares) |
| 2022-09-30 |
1,261 |
| 2022-06-30 |
1,260 |
| 2022-03-31 |
1,262 |
| 2021-12-31 |
1,262 |
| 2021-09-30 |
1,262 |
| 2021-06-30 |
1,260 |
| 2021-03-31 |
1,262 |
| 2020-12-31 |
1,263 |
| 2020-09-30 |
1,261 |
| 2020-06-30 |
1,255 |
| 2020-03-31 |
1,270 |
| 2019-12-31 |
1,277 |
| 2019-09-30 |
1,267 |
| 2019-06-30 |
1,277 |
| 2019-03-31 |
1,283 |
| 2018-12-31 |
1,308 |
| 2018-09-30 |
1,307 |
| 2018-06-30 |
1,308 |
| 2018-03-31 |
1,320 |
| 2017-12-31 |
1,319 |
| 2017-09-30 |
1,319 |
| 2017-06-30 |
1,317 |
| 2017-03-31 |
1,320 |
| 2016-12-31 |
1,358 |
| 2016-09-30 |
1,339 |
| 2016-06-30 |
1,355 |
| 2016-03-31 |
1,412 |
| 2015-12-31 |
1,521 |
| 2015-09-30 |
1,503 |
| 2015-06-30 |
1,540 |
| 2015-03-31 |
1,569 |
| 2014-12-31 |
1,647 |
| 2014-09-30 |
1,637 |
| 2014-06-30 |
1,664 |
| 2014-03-31 |
1,680 |
| 2013-12-31 |
1,695 |
| 2013-09-30 |
1,692 |
| 2013-06-30 |
1,695 |
| 2013-03-31 |
1,665 |
| 2012-12-31 |
1,583 |
| 2012-09-30 |
1,585 |
| 2012-06-30 |
1,561 |
| 2012-03-31 |
1,555 |
| 2011-12-31 |
1,580 |
| 2011-09-30 |
1,563 |
| 2011-06-30 |
1,602 |
| 2011-03-31 |
1,624 |
| 2010-12-31 |
1,747 |
| 2010-09-30 |
1,694 |
| 2010-06-30 |
1,798 |
| 2010-03-31 |
1,857 |
| 2009-12-31 |
1,868 |
| 2009-09-30 |
1,865 |
| 2009-06-30 |
1,869 |
| 2009-03-31 |
1,885 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$104.541B |
$27.305B |
|
Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.
|
